Skip to main content

Food Hypersensitivity

4
Pipeline Programs
3
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 5 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
5 programs
2
2
Baked MilkPhase 21 trial
Open label peanut OITPhase 21 trial
Baked MilkPhase 11 trial
E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3Phase 11 trial
A Registry for the Food Allergy CommunityN/A1 trial
Active Trials
NCT04653324Recruiting23,000Est. Aug 2027
NCT00578656Completed220Est. Feb 2011
NCT00850668Completed15Est. Oct 2010
+2 more trials
Genentech
GenentechCA - Oceanside
1 program
OmalizumabPHASE_2Monoclonal Antibody

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Allergy TherapeuticsOpen label peanut OIT
Allergy TherapeuticsBaked Milk
Allergy TherapeuticsE. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3
Allergy TherapeuticsBaked Milk
Allergy TherapeuticsA Registry for the Food Allergy Community

Clinical Trials (5)

Total enrollment: 23,425 patients across 5 trials

NCT01814241Allergy TherapeuticsOpen label peanut OIT

Mechanisms of Desensitization During Peanut Oral Immunotherapy

Start: Apr 2013Est. completion: Dec 201520 patients
Phase 2Completed

Study of Milk Allergy and Tolerance in Children

Start: Aug 2008Est. completion: Nov 2014170 patients
Phase 2Completed
NCT00850668Allergy TherapeuticsE. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3

Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults

Start: Oct 2009Est. completion: Oct 201015 patients
Phase 1Completed

An Interventional Study of Milk Allergy

Start: Jun 2004Est. completion: Feb 2011220 patients
Phase 1Completed
NCT04653324Allergy TherapeuticsA Registry for the Food Allergy Community

A Registry for the Food Allergy Community

Start: Aug 2017Est. completion: Aug 202723,000 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 23,425 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Food Hypersensitivity | Pipeline & Competitive Landscape | Formulate